Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism
Paul M. Ridker(Herlev Hospital), Robert J. Glynn(Brigham and Women's Hospital), Samuel Z. Goldhaber(Brigham and Women's Hospital), Mary Cushman(University of Vermont), C. Gregory Elliott(National Institutes of Health), Stephan Moll(University of North Carolina at Chapel Hill), Craig M. Kessler(Georgetown University), Steven R. Deitcher(Cleveland Clinic), Henri Bounameaux(University of Geneva), Rolf Paulson(Altru Health System), Ellie Danielson(Brigham and Women's Hospital), Charles S. Eby(Washington University in St. Louis), Bruce A. Schwartz(Clinical Research Consultants (United States)), Kenneth A. Bauer(VA Boston Healthcare System), Turnly Wong(St. Boniface Hospital), Joseph P. Miletich(Washington University in St. Louis), Yves Rosenberg(National Institutes of Health)
Cited by 809
Related Papers
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Heart Disease and Stroke Statistics—2018 Update: A Report From the American Heart Association
|Circulation|2018|7.2k
Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular Events
|New England Journal of Medicine|2002|3.6k
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k